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ABSTRACT 
 
      Breast cancer cells overexpress EpCAM that can be used as a marker to select breast cancer CTCs 
from heterogeneous clinical samples, even when present in low abundance.  This study used MDA-MB-
231 cells which have a low expression level of EpCAM (1.7 x 103  binding sites per cell.3) Herein, we will 
report on the use of antiEpCAM antibodies immobilized onto the surface of a capture bed poised within a 
PMMA microchip that was fabricated into an HTMSU used for selection of breast cancer CTCs seeded 
into a buffer solution. The microchannel walls within the capture bed were UV modified for 5, 10, 15 and 
20 min and covalently decorated with antiEpCAM antibodies of varying concentrations (0.25, 0.5, 1.0 
and 2.0 µg/µL) using an EDC-NHS coupling reaction. The HTMSU capture bed consisted of 51 high-
aspect ratio microchannels (35 µm width × 150 µm depth) that were replicated in PMMA, from a metal 
mold master. Cultured breast cancer CTCs were fluorescently stained using a fluorescent isothiocyanate 
staining kit.  The microfluidic device was infused with the fluorescently stained breast cancer CTCs at a 
flow rate of 27.5 uL/min.  The capture of the cells was observed and visually quantified using a Zeiss 
inverted optical microscope.   
      Percent recoveries of breast cancer CTCs were obtained using HTMSUs that were UV modified for 5, 
10, 15 and 20 min.  The optimal percent recovery was 81.6% after 10 min of UV modification.  Varying 
concentrations (0.25, 0.5, 1.0 and 2.0 µg/µL) of antiEpCAM antibodies were used and percent recoveries 
as low as 71.4% and as high as 81.6% were achieved using 0.25 and 1 µg/µL of antiEpCAM antibody 
respectively.   
       Lastly, another method for decorating the microfluidic channels with antiEpCAM antibodies was 
explored.  Using 2 min exposure to plasma oxidation, antiEpCAM antibodies were immobilized to the 
microchannel walls. Following the same cell selection protocol used for the UV modified HTMSU, a 
mean percent recovery of 50% was obtained. The combination of carboxylate, oxides and anhydride 
groups formed due to plasma oxidation, instead of exclusively carboxylate groups that form due to UV 
modification could be a contributing factor to this lower recovery. 
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CHAPTER 1. CIRCULATING TUMOR CELLS (CTCs) 
1.1. Low Abundance Cells 
 
     The enumeration and analysis of low abundance cells is advantageous because of its various 
applications such as cancer research, forensic science, homeland security and environmental analysis. 
Low abundance cells are described as cells that are present at concentrations less than 1,000 cells/ volume 
of fluid. 1 Some typical examples of low abundance cells are circulating fetal cells, stem cells and 
circulating tumor cells (CTCs). A major challenge that affects the analysis of low abundance cells is the 
selection of target cells from a heterogeneous population in which the target is the minority.  There are 
four important metrics that must be considered for the isolation of low-abundance cells: (a) Throughput, 
the number of cell identification or sorting steps per unit time; (b) recovery, an indicator of target cells 
collected from the input sample; (c) purity, which depends on the number of interfering cells excluded 
from the final analysis; and (d) viability, which describes whether or not the isolated cells retain their 
biological function after the selection process.2, 3 
1.2 Significance of CTC Analysis 
 
      The challenge of selecting low abundance cells from a heterogeneous population is exemplified in the 
analysis of CTCs, especially those that have low expression levels of EpCAM. 
  CTCs are cells that are released from a primary tumor into circulation and carried to a secondary site, 
where they can spawn metastatic disease.1 CTCs can be generally defined as nucleated cells that lack 
CD45 and express cytokeratin(s).4, 5 Cytokeratin is an epithelial subgroup of a class of proteins termed 
intermediate filaments (IF).  IF proteins are used in pathology for the classification of normal and 
malignant cells on a molecular basis. In recent years, many investigators have outlined a variety of 
applications of CK polypeptides as diagnostic markers in tumor pathology, particularly for the differential 
diagnosis of carcinomas at the histologic level.   
      An antibody to the membrane antigen epithelial cell adhesion molecule (EpCAM) is used to identify 
cells of epithelial origin circulating within the blood.6 Additionally, cytokeratin antibodies can be used to 
further distinguish CTCs as those that are not white blood cells (i.e. - CD45 negative) and select for 
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carcinomas..7 
     CTCs were first discovered by the Austrian physician, Thomas Ashworth, in the autopsy of a patient 
who succumbed to advanced metastatic cancer and were reported in 1869.8     In 1889, the seed and soil 
hypothesis for understanding the process of metastasis was proposed by Paget.9  He hypothesized that 
metastatic spread was the result of particular tumor cells (seeds) finding a feasible environment (soil) in 
which to develop and grow.  An alternative hypothesis of mechanical entrapment was proposed by 
Ewing.11 In 1928, Ewing suggested that CTCs accumulate through entrapment in the first vascular bed 
they encounter.   
      Metastasis can be described as the process in which cancer cells leave the primary tumor site, 
disseminate and form secondary tumors at anatomically remote sites.10  CTCs have also been observed in 
animals that were implanted with experimental tumors.  The cells were seen to be released into the blood 
and it was also shown that trauma produces an increased release of CTCs and an increase in metastasis. It 
was calculated that 1x105 cells were released per day in a highly metastatic tumor system.11 
Based on these hypotheses, metastasis is often described as a cascade of events (Figure 1.1), because 
there are a series of steps that are involved: (1) Angiogenesis, which is the development of a new blood 
supply for the proliferating cells; (2) tumor cells eluding from the primary tumor mass; (3) migration and 
incursion of tumor cells through the basement membrane (BM) and extracellular matrix (ECM) 
surrounding the tumor epithelium and invasion of the BM supporting the endothelium of local blood 
vessels; (4) intravasation of the tumor cells into the blood vessel before traveling hematogeneous 
(lymphagenous) dissemination to distant anatomical sites; (5) CTC adhesion to the endothelial cell lining 
at the capillary bed of the target organ site; (6) tumor cells incursion through the endothelial cell layer and 
surrounding BM (extravasation) and target organ tissue; and (7) secondary tumor foci growth at the target 
organ site.10, 11, 12 
     The formation of new blood vessels from pre-existing vasculature is termed angiogenesis.13  The 
formation of an intra-tumor blood supply gives tumors the ability to obtain the oxygen and nutrients 
necessary to flourish.  The release of growth factors, such as vascular endothelial growth factor (VEGF) 
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and fibroblast growth factor (FGF) stimulate angiogenesis. Through angiogenesis, tumors are able to gain 
access to a blood supply in conjunction with co-option of existing blood vessels and also vasculogenic 
mimicry, which causes the tumor cells to carve blood vessel-like conduits. 14 
 
Figure 1.1 The metastatic cascade. Tumor cells are released from the primary tumor mass, and thus 
become circulating tumor cells (CTCs). The CTCs in the blood are subjected to the shear forces generated 
by the flow of blood, immune response attack and anoikis. CTCs that do survive can reach a target organ 
and attach to the endothelial cell lining within the capillary bed of the target site. After invading the 
endothelium, a secondary tumor mass can develop. Reprinted with permission.11 
 
The initial phases of dissemination are promoted by the loss of cell-cell adhesion within the primary 
tumor mass, which permits disaggregation.14  Cadherin/catenin expression in the primary tumor is also 
altered and results in the loss of cell–cell adhesion. Abrogration of E-cadherin has been reportedly 
associated with the metastatic phenotype.15  Dissolution of the ECM during metastasis occurs through the 
action of several hydrolytic enzymes, released either by the tumor cells themselves or by cells 
surrounding the tumor cells.16  
      Following their release from the primary tumor site, many cancer cells possess the ability to migrate 
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in several different ways: (1) Moving together as groups or as single cells; (2) assuming an elongated 
mesenchymal morphology; or (3) crawling in an amoeboid fashion.  Initially, tumor cells attach to the 
BM and ECM through interactions with the integrin family of adhesion receptors and subsequently 
traverse these structures as proteolytic enzymes aiding their invasion and ultimately allowing the tumor 
cells access to the vasculature.12 Tumor cells also can physically deform their shape in order to move 
through collagenous matrices. 17 
    Detached tumor cells are allowed to pass into systemic circulation, because of endothelial cells’ ability 
to retract. CTCs in the blood stream are subject to events in the blood stream that threaten their survival 
including the shear forces generated by the flow of blood and an immune response attack.17  Once the 
CTCs are shed, they are fragile and lack interactions with blood borne fibrin and platelets and 
consequently, the membrane can be easily destroyed by shear stress imparted by blood flow.17 
1.3 Evidence for Breast Cancer CTC in Early Metastasis 
The majority of current understanding of the processes involved in cancer metastasis has been 
originated from mouse models of metastasis.18  Originally, it was believed that metastasis is an event that 
occurred late in cancer progression, but evidence gathered from CTCs has shown that metastasis may be 
an early event.19 This is also supported by the fact that CTCs have been discovered in patients with early 
breast cancer.19 
       A study recently conducted by Husemann et al. utilizing transgenic (HER2/PyMT) mice showed that 
dissemination of tumor cells can occur at the pre-invasive stage of the primary tumor.20   Cancer cells that 
are transported through the circulation from the primary tumor to vital organs throughout the body, 
initiate blood-borne metastasis.  This mechanism is directly responsible for the majority of cancer related 
deaths.18 
      Tumor cells that express invasive phenotypes lose many types of epithelial antigens in a 
transformation process called epithelial-mesenchymal transition (EMT).21 The loss of epithelial antigens 
occurs when non-motile epithelial cells with regular cell-cell junctions and adhesion, lose their cell-cell 
junctions and convert into individual, motile and invasive mesenchymal phenotypic cells.21 These 
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processes are consistent with the acquisition of a “cancer stem-like cell” phenotype that is also known as 
“stemness” or cancer stem cell (CSCs) characteristics.21 The EMT is a dynamic and reversible process, 
which has been observed in patient tissues to display a wide spectrum of phenotypes.22 EMT occurs early 
in cancer progression and involves tumor progenitor (TP) cells with stem/invasive cell properties. These 
types of cells may enter the circulation to generate multiple populations of CTCs with specific phenotypes 
that could contribute to aggressive growth of tumor cells and to early metastatic colony formation.23 EMT 
is known to induce tumor cell motility, aggressiveness and invasiveness, therefore promoting metastasis 
of solid carcinomas.24 
1.4 Breast Cancer CTCs 
 
     CTCs have been detected in the majority of epithelial cancers, such as prostate, lung, colon and breast, 
which is the focus of this thesis.25  The prognoses for women with metastatic breast cancer (MBC) 
represent a heterogeneous group and can vary depending on factors such as age, tumor hormone-receptor 
status and grade, anatomic site, and extent of disease, as well as the status of any conditions and 
associated performance status. Breast cancer is one of the most common cancers that afflict women.  The 
American Cancer Society reports that in 2010, approximately 207,090 new cases of invasive breast cancer 
were diagnosed and of those, 39,840 women died from metastatic disease. These statistics make the need 
for novel approaches for breast cancer diagnosis more urgent.19   
     CTCs in breast cancer patients have been shown to be an indicator of poor prognosis when the CTC 
level in circulation exceeds a particular level. The presence of high CTC counts (≥5 per 7.5 mL of whole 
blood) is associated with shorter progression-free (PFS) and overall survival (OS) in the metastatic 
setting.26 Progression free survival describes the length of time during and after treatment that the disease 
being treated does not get worse.  Overall survival differs from PFS in that it involves the percentage of 
cancer patients in a group that will stay alive after a certain period of time.22 The prognostic value of 
CTCs is unrelated to hormonal receptor status, sites of recurrence, and previous treatments, and has been 
demonstrated superior to tumor burden, suggesting a further peculiar biological value.26  
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1.5 Utility of CTCs in a Clinical Setting 
  
     Increasingly advanced and sensitive technologies to isolate human CTCs have emerged and provide 
the opportunity to extend studies of cancer metastasis directly to human cancer.18 Potential applications 
for CTC analyses include real time noninvasive monitoring of CTCs as biomarkers of either sensitivity or 
acquired resistance to new cancer therapies and identifying new potential therapeutic targets to directly 
suppress cancer.18   
     There are challenges to be considered involving CTCs in the clinical setting.  Studies have shown 
remarkably varying CTC numbers ranging from <5 to thousands per mL in the same category of 
patients.26 These differences in CTC numbers could be caused by cancer biology or varying sensitivity of 
techniques used, but clarification of these possibilities is still necessary. Ultimately, the heterogeneity of 
breast cancer subtypes makes it difficult to rely on a single, universally expressed and specific marker.26   
       Despite these challenges, the enumeration of CTCs has been shown to offer information regarding 
patient prognosis and may be able to provide oncologists with information about patient response to 
systemic therapy shortly after its initialization.26 Ideally, physicians would be able to determine a patient’s 
sensitivity or resistance to planned treatment and identify indicators of good and poor prognosis.  They 
will also be able to detect markers of resistance that may be forming during the treatment.27 
     There are two types of distinct marker types that are expressed on CTC membranes, tumor type-
specific and epithelial-specific markers.28 Tumor type-specific markers are expressed only by tumor cells 
that have disseminated from a particular tumor. Examples of this type of marker include mammoglobin, 
HER2-neu, mucin 1 (breast cancer), prostate specific antigen (prostate cancer), and carcinoembryonic 
antigen (colorectal and gastric cancers). 4, 29  These types of markers not only offer the potential 
advantages of specifically identifying a particular organ tumor cell rather than just epithelial cells but they 
also provide some insight into their molecular characteristics. 30  
The most frequently used CTC isolation techniques often rely on antibody-based capture of CTCs, 
which express epithelial cell surface markers that are not present in normal leukocytes.4, 26 Of these 
epithelial cell surface markers, epithelial cell adhesion molecule (EpCAM) is most commonly used 
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because its expression is virtually universal in cells of epithelial origin, and it is also absent in blood 
cells.18 In primary and metastatic breast cancers, EpCAM is expressed at levels that are 100- to 1,000 
times greater than in benign epithelial cells, and is thought to be linked to tumor invasion and migration. 
The overexpression of EpCAM in carcinomas has been found to be associated with poor prognosis and 
therefore leads to the evaluation of EpCAM as a potential therapeutic target for patients with advanced 
carcinomas.31  
1.6 CTC Morphology   
 
In order to possess the capability to capture CTCs, technological platforms have been developed that 
exploit the observation that CTCs have a larger median diameter (15 µm) than normal cells (11 µm) 27 
Solid tumor cells (STCs) have a slightly larger nuclear/cytoplasmic (N/C) ratio compared to CTCs 
(CTCs-27.1%, STCs-28.9%).28  CTCs have a round or oval morphology while STCs and even cultured 
CTCs have irregularly-shaped nuclei.  Many CTCs contain conspicuous intracellular compartments that 
contain multiple small vesicles and large amounts of amorphous material.  A ribosome decorated 
membrane also surrounds these CTCs; these inclusions could have a size that is equal to or exceeds that 
of the nucleus and are not seen in STCs. 8 
1.7 Macroscale Method for CTC Analysis: Cell SearchTM  
The first and only CTC isolation device to obtain FDA approval is the CellSearchTM system. 
  
Figure 1.2 (A-C) Schematic of the immunomagnetic-assisted cell-sorting process. Blue and tan circles 
represent normal and circulating tumor cells, respectively. 33 
 
It is an immunomagnetic isolation system for selecting CTCs from peripheral blood samples using 
	   8	  
positive selection (Figure 1.2) with EpCAM used as the antigenic marker.  
This system uses magnetic beads that are conjugated to monoclonal antibodies directed against 
EpCAM. The processed sample is first enriched with ferromagnetic particles coated with anti-EpCAM 
antibodies for selecting the CTCs.  Following this, density gradient centrifugation is utilized along with a 
series of washes, in order to remove the red blood cell (RBC) fraction from the sample. These 
immunomagnetically-labeled cells are then isolated by an external magnetic field. After magnetic 
isolation, the cells are incubated with phycoerythrin-conjugated anti-cytokeratin antibodies that 
specifically recognize cytokeratins to identify epithelial cells, an antibody against CD45 conjugated with 
allophycocyanin to identify contaminating leukocytes, a nuclear dye [4, 6-diamidino-2-phenylindole 
(DAPI)] to fluorescently label the cell nucleus, and a permeabilization buffer to allow cytokeratin 
antibodies to enter into the CTCs. 18, 31   
 
Figure 1.3 (A) Gallery of images that has been screened for CTCs. Three CTCs are marked 
in the composite image, which are positive for DAPI and cytokeratin-phycoerythrin (green) but negative 
for CD45-APC (allophycocyanin) and in the FITC (fluorescein) channel. (B) DAPI staining of nuclei and 
(C) cytokeratin-positive CTCs.31  
 
      The CellSearch system has a recovery of about 60%.  Some of the limitations with this system include 
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its low throughput, modest recovery and purity and high input volume required.31 
The theory that the presence of breast cancer CTCs effects overall survival rate was investigated by 
Cristofanilli et. al using CellSearchTM One hundred and seventy five patients with measured MBC were 
involved in the study, 83 of these were beginning first line treatment and were the focus of this study.  A 
7.5 mL of whole blood sample was drawn prior to treatment initiation and monthly for 6 months 
thereafter and were isolated and quantified using immonomagnetics.30 
Figure 1.4 shows Kaplan-Meier plots for prediction of PFS and OS using baseline CTC numbers  
 
Figure 1.4. Kaplan-Meier plots of progression-free survival (PFS) and overall survival (OS) in first-line 
therapy MBC patients with less than five circulating tumor cells (CTCs; top lines) or five CTCs (bottom 
lines) at baseline (A and D), first follow-up visit (B and E), and restaging (C and F). PFS and OS were 
calculated from the time of the baseline blood draw. Coordinates of dashed lines indicate median survival 
time. 30 
 
(Figs 1.4A and D, n=83 patients), the first follow-up CTC numbers (Figs 1.4B and E, n=60 patients), and 
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the CTC numbers at restaging (Figs 1.4C and F, n =79 patients). Forty-three of the patients (52%) had ≥ 5 
CTCs per 7.5 mL of blood at baseline. These patients had a notably shorter median PFS (~4.9 months; 95% 
CI, 2.0 to 8.1 months) and median OS (~14.2 months; 95%CI, 11.1 to >18 months) in comparison to 
patients with <5 CTCs per 7.5 mL of blood (median PFS, ~9.5 months; 95% CI, 6.1 to > 18 months; P 
= .0014; median OS >18 months; P<.0048). Baseline CTC number was almost always associated with 
PFS in patients whose initial therapy was chemotherapy. Cristofinilli concluded that the presence of 5 or 
more CTCs in 7.5 mL of blood at the time of diagnosis of metastatic breast cancer and preceding 
initiation of first line therapy is linked to short PFS and OS.30 
1.8 Methods of CTC Analysis Using Microfluidics 
     There are several characteristics that a platform for capturing CTCs should possess, such as high 
sensitivity, meaning it has the ability to detect every single CTC. It should also demonstrate a high level 
of purity.  Most importantly, this method should preserve the CTC viability and morphology.24 Current 
methods for CTC isolation have attempted to exploit characteristics that are specific to CTCs.  
       There have been many recent technological advances for the detection and analysis of CTCs. 
Microfluidic devices provide important advantages over other purification techniques because they enable 
highly efficient processing of complex fluids while causing minimal damage to sensitive cell 
populations.34 One such method for CTC analysis is the microfluidic device developed by Nagrath et. al 
termed the “CTC chip” (Figure 1.5 B).35  This “first generation” device has the ability to efficiently and 
reproducibly isolate CTCs from the blood of patients with common epithelial tumors. The microfluidic 
system (Figure 1.5C) consisted of a microfluidic chip etched in silicon (Fig. 1.5B), a manifold that 
encloses the chip (Figure 1.5C), and a pneumatic pump (Figure 1.5A) that establishes the flow through 
the capture module (Figure 1.5C).  The chip has dimensions of 25 mm × 66 mm, with an active capture 
area of 19 mm × 51 mm. It consisted of an equilateral triangular array of microposts, 100 µm tall and 100 
µm in diameter with an average 50 µm gap between microposts. In order to increase the hydrodynamic 
efficiency, the repeated patterns of equilateral triangular arrays were shifted vertically by 50 µm for every 
three rows throughout the chip to ensure maximum interactions between micropost structures and cells. 
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This array incorporated 78,000 microposts within a surface area of 970 mm2. The chip employed deep 
reactive ion etching (DRIE) for its fabrication.33 
     The two essential operating parameters for controlling the efficiency of cell capture are sample flow 
velocity and shear force. The flow velocity controls the length of time that the cell interacts with the 
micropost.  The shear force must be kept low to ensure that the cells are adequately attached to the 
micropost.   
 
Figure 1.5 Isolation of circulating tumor cells (CTCs) from whole blood, performed with a CTC chip. (A) 
The workstation setup for CTC isolation from whole blood. (B) The CTC chip with microposts etched 
into the silicon. (C) Micrograph of whole blood flowing through the CTC chip. (D) An image of a 
captured NCI-H1650 lung cancer cell spiked into blood. The inset shows a high-magnification view of the 
captured cell. (E) CTC recovery as a function of flow rate. (F) Regression analysis of capture efficiency 
for various target-cell concentrations in whole-blood samples versus lysed-blood samples. (G-N) High-
magnification images of captured CTCs and hematologic cells stained with 4‘,6-diamidino-2-
phenylindole (DAPI), cytokeratin, and CD45. Merged images identify CTCs in panels G, I, K and M and 
hematologic cells in panels H, J, L and N33 
 
     Using a flow rate of 1 ml/h, 65% of the CTCs were recovered, and 98% of the cells remained viable.  
The maximum shear stress that cell near the micropost surface experienced was 0.4 dyn cm−2 at θ = 68°. 
Overall, this CTC chip has the ability to identify large numbers (99%, 40% purity) of viable CTCs 
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without the use of pre-processing steps.33 
Adams et al. introduced a high throughput microsampling unit (HTMSU) that was fabricated from 
PMMA and capable of isolating intact CTCs from peripheral blood and directly quantifying the CTC 
following isolation and enrichment.36  The device, shown in Figure 1.6, consisted of a series of 51 high 
aspect ratio channels that were linear or sinusoidally configured with a shared set of input/output ports.    
 
Figure 1.6 Schematic of a microchip-based high-throughput microsampling unit (HTMSU) fabricated in 
poly (methylmethacrylate) via microreplication for selection of circulating tumor cells (CTCs). (A) An 
AutoCAD® diagram of the sinusoidally shaped capture channels with bright-field optical micrographs 
showing (B) the integrated conductivity sensor consisting of cylindrical Pt electrodes with a 75 µm 
diameter and a 50 µm gap; (C) the single port exit, where the HTMSU‘s width tapers from 100 µm to 50 
µm and the depth tapers from 150 µm to 80 µm over a 2.5 mm region that ends 2.5 mm from the Pt 
electrodes; (D) the sinusoidal cell-capture channels (5x magnification); (E) three-dimensional projection 
of the topology of the HTMSU obtained at 2.5 µm resolution via noncontact optical profilometry (arrows, 
Pt electrode conduits); and (F) the capture efficiency of CTCs in spiked whole-blood samples as a 
function of the cells‘ translational velocity. The microchannels were 35 µm wide (red down triangles, 
sinusoid; purple circles, straight) and 50 µm wide (blue up triangles).34 
 
Using the MCF-7 cell line from a metastatic breast cancer patient, capture efficiencies up to 97% 
were obtained and 1 mL of sample was processed in ~37 min. The captured CTCs were removed from the 
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capture surface using trypsin and counted individually using conductivity detection.34 
      In 2010, Stott et al. introduced a high throughput microfluidic device, the herringbone chip (HB chip), 
which allowed cells to have adequate contact with antibody-coated surfaces.32 This device effectively 
captured CTCs from patients with metastatic prostate cancer.  The HB-chip was composed of a 1” x 3” 
glass slide bonded to a polydimethylsiloxane (PDMS) structure that contained 8 microchannels fabricated 
with patterned herringbones on their upper surface (Figure 1.6).  The internal walls of the device were 
chemically activated by in-line functionalization and coating with antibodies against EpCAM.  The 
geometric design was based on low Reynolds’ numbers (Re).  Re is a critical non-dimensional parameter 
used in microfluidics to characterize the flow stability, which is given by; 
Re = ρUdh / µ         (Equation 1) 
 
where ρ is the fluid density, U is the fluid velocity, µ the viscosity of the fluid, and dh is the  
 
hydraulic diameter of the channel, given by;  
 
dh = 4wh/2(w + h)= 2wh/w + h           (Equation 2) 
 
Low Re numbers indicate laminar flow.  If the Reynolds number is greater than 2000, the flow would be 
characterized as turbulent, and therefore would not be conducive for maintaining the viability of CTCs.34 
This HB-chip was adapted to isolate rare cells from whole blood by varying the ratio of height of the 
grooves to that of the channel, chevron dimensions and periodicity (Figure 1.6 B).  The herringbone 
grooves were staggered periodically so that each mixing cycle was defined by two sequential regions of 
ten asymmetrically shifted chevrons.  The final dimensions of the device were: overall height of channel 
(h) 50 µm, ratio of the height of the grooves to that of the channel (α) set to 0.8; angle between the 
herringbones and the axis of the channel (θ) 45°, and principal wave vector q = 2π/100 µm.  There was 
also a branching inlet header that was designed to feed into eight individual channels to promote 
mechanical integrity and uniform flow distribution across the device. 32   This “second generation” device 
offered higher blood volume throughput, and increased CTC capture efficiency and purity. This device 
also provided imaging benefits because of its transparent walls.  It possessed less complex three-
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dimensional structures that greatly facilitated scale up device production, thus enabling the initiation of 
larger-scale clinical studies. 
 
Fig. 1.7. (A) The HB-Chip consists of a microfluidic array of channels with a single inlet and exit. Inset 
illustrates the uniform blood flow through the device. (B) A micrograph of the grooved surface illustrates 
the asymmetry and periodicity of the herringbone grooves.32 
 
     In the initial proof of principle experiments, the HB-chip isolated CTCs from 14 of 15 (93%) patients 
with metastatic prostate cancer (median 63 CTCs ⁄ mL) and allowed for RNA-based detection of the 
TMPRSS2-ERG fusion transcript, showing a further improvement over the previous generation CTC-
Chip reported by Nagrath.32, 33 
1.9 Conclusions 
Evidence has shown that CTCs play a prognostic role in both early and metastatic breast cancer 
patients.19, 20 In early breast cancer, the presence of CTCs can allow clinicians to identify those patients at 
risk for recurrence and therefore may benefit from additional therapy. In both 
early and metastatic breast cancer patients, CTCs are an easily obtainable option for monitoring treatment 
efficacy, as they can be collected simply by the drawing of peripheral blood.19  CTC assessment has been 
repeatedly shown to be a strong and reliable predictor of outcome in metastatic breast cancer. While the 
mechanism of CTC generation through release from a primary tumor site is not fully understood, CTCs 
remain a unique and heterogeneous cell population with established prognostic and predictive value in 
MBC and more specifically, in defined subtypes of breast disease and may be related to bone biology in 
particular.7 
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CHAPTER 2. CAPTURE AND ENUMERATION OF BREAST CANCER CTCs WITH LOW 
EpCAM EXPRESION LEVELS USING anti-EpCAM ANTIBODIES IMMOBILIZED TO A 
MICROFLUIDIC POLYMERIC DEVICE  
 
2.1 Introduction 
Breast cancer is the most frequently diagnosed non-cutaneous cancer and remains the second 
leading cause of cancer deaths among women in the United States.1 It is estimated that out of 8 
women at least 1 will develop an invasive breast cancer at some point during her lifetime. 
Conventionally, contrast enhanced magnetic resonance imaging has been used to evaluate 
women who have been diagnosed with breast cancer.1  Unfortunately, despite optimal and 
systemic adjuvant treatment, 30-40% of patients diagnosed with curable breast cancer will face 
fatality. These facts demand the need for novel approaches for breast cancer diagnosis, prognosis 
and treatment, which could potentially be accomplished using breast cancer CTC analysis.  
      This project will investigate the utility of a microfluidic device that possesses a 51 channel capture 
bed that has been covalently decorated with anti-EpCAM antibodies directed against breast cancer CTCs.2  
In particular, we were interested in selecting CTCs that possess low expression levels of EpCAM because 
many clinical samples contain CTCs that are heterogeneous including the amount of EpCAM they 
express. CTCs that have low expression levels of EpCAM can be difficult to collect because the low 
EpCAM expression level can induce poor adhesion to the surfaces decorated with anti-EpCAM 
antibodies. To evaluate the ability to select CTCs with low EpCAM expression levels, the MDA-MB-231 
breast cancer cell line was used in this study because it possesses a low EpCAM expression level; 1.7 x 
103  binding sites per cell.3 This expression level is so low, that MDA-MB-231 cells are often 
characterized as EpCAM negative.3 The aforementioned microfluidic device has been used to obtain high 
recoveries (>97%) of breast cancer CTCs with high EpCAM expression levels (MCF-7).2  The MCF-7 
breast cancer cell line has an EpCAM expression level of 222.1 x103 binding sites per cell.3   
       EpCAM, the epithelial cell adhesion molecule, is a glycoprotein encoded from the GA-733-2 gene 
located on chromosome 2.4 EpCAM expression is restricted to and broadly expressed by cells of epithelial 
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origin.5 The overexpression of EpCAM has been reported in carcinomas and is associated with poor 
prognosis. Expression of EpCAM in various carcinomas has led to research to evaluate the use of anti-
EpCAM antibodies as possible a treatment for patients diagnosed with metastatic cancer.4  Osta et al. 
demonstrated that EpCAM is highly overexpressed in primary and metastatic breast cancer. EpCAM has 
also been determined to be a contributor to the proliferation, migration, and invasion of breast cancer 
cells.5  The specific noncovalent interactions between a ligand, such as an EpCAM antibody, and a target-
specific receptor, EpCAM, is exploited through the use of affinity based selection of CTCs.6 Positive 
selection occurs when a target cell is directly captured through the use of a membrane protein that is 
unique to that cell type and its associated antibody.7 Cell selection consists of a solid phase in which (a) 
the recognition element(s) is covalently tethered to the surface and (b) the sample containing the CTCs is 
moved through a conduit to facilitate the selection process.7 Other factors that play a role in the efficiency 
of the interaction between the cell’s membrane antigen and surface-bound antibody are: (a) Non-specific 
interactions; (b) target cell-recognition element adhesion strength; (c) conduit architecture; (d) recognition 
element immobilization chemistry; and (e) ligand surface density.7  
The cell/surface antibody adhesion force (FA) is critical to affinity-based cell selection that uses 
surface-immobilized recognition elements and flow processing because large FA of the target cell to the 
surface enhance the recovery.7 The FA between the cell and antibody-decorated surface must be greater 
than the shear force (FS) generated by the solution flow to prevent target cell loss.  
      FA can be calculated from the bond strength between a single antigen-antibody complex (fc), the cell-
contact area with the recognition surface (Ac), and the number of limiting receptor sites poised within the 
contact area of the cell to the surface (Cs). The number of receptor sites is either determined by the load 
level of antibodies to the surface or the expression level of the antigen on the CTC. In most cases, Cs is set 
by the antibody surface density, however, in the case of CTCs that have low expression levels of 
EpCAM, Cs is determined by the surface concentration of the antigens. FA is calculated from Equation 1,2 
FA = fc x Ac x Cs .        (Equation 1) 
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Once the cell adheres to the capture surface, the contact area can be calculated from Equation 2, if the cell 
is assumed to be a non-deformable object. 2 
Ac = π{rpsin[cos−1(rp –h‘+h)/rp]}2       (Equation 2) 
 
where rp is the cell radius and h and h’	  represent the characteristic cell-separation distances from the 
surface upon binding. For MCF-7, which has an EpCAM expression level of 5.1 x 105 per cell, the 
adhesion strength was calculated to be 0.26 dynes assuming a non-deformable object.2  In the case of 
MDA-MB-231 cells, where the EpCAM expression level is 1.7 x 103 per cell, FA is now equal to 0.0013 
dynes. Therefore, a larger contact area (Ac) would be required to for the MDA-MB-231 cells to provide 
sufficient adhesion strength to minimize loss during flow processing (see below). 
In the event that the shear force, FS, generated by the flow is equal to or greater than FA, the cell can 
be removed from the surface. The velocity-dependent FS can	  be	  determined	  from	  Stoke‘s	  law,	  Equation	  3,2 
FS =6πηrpνc                 (Equation 3) 
where rp is the cell radius, η	  is the solution viscosity, and νc is the critical linear velocity that can induce 
cell detachment. 
      Wang et al. demonstrated the utility of a three-dimensionally (3D) nanostructured substrate coated 
with anti-EpCAM antibodies that has the ability to isolate CTCs from whole blood.8  A silicon-nanopillar 
(SiNP) array was used to allow for enhanced interactions between the SiNP substrates and nano-scale 
components of the CTC surface, which ultimately resulted in improved cell-capture affinity in 
comparison to unstructured substrates.	   
The 3D nanostructured cell capture substrates were prepared by fabricating densely packed 
nanopillars with diameters of 100-200 nm on silicon wafers using a wet chemical etching method.8  
SiNPs were created with lengths ranging from 1-20 µm by applying different etching times.  The N-
hydroxysuccinimide (NHS)/maeimide chemistry was used to introduce streptavidin to the surface of the 
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SiNP.  Following this biotinylated anti-EpCAM antibody was added to the streptavidin coated substrates 
to create an anti-EpCAM antibody immobilized substrate.  An MCF-7 cell suspension was introduced 
onto a 10 µm long SiNP surface and incubated for an hour. In parallel, a flat Si substrate modified with 
anti-EpCAM antibodies was also examined as a control.  The substrate immobilized cells were visualized 
using fluorescence microscopy.  It was determined that the SiNP substrates could capture up to ten times 
more cells than the flat Si substrates.  Flat Si substrates only achieved capture yields of 4-14% as opposed 
to 45-65% on SiNP substrates. It was concluded that the 3D nanostructures are possibly responsible for 
the enhanced cell capture yields.  This conclusion was drawn from the fact that enhanced topographic 
interactions between the 3D nanostructured substrates and extracellular extensions existed, in addition to 
anti-EpCAM antibody/EpCAM biological recognition.8 
      This chapter will explore the generation of unique surface architectures for the high efficiency 
recovery of low expression level EpCAM expressing cells, such as MDA-MB-231 breast cancer cells. In 
particular, we will look at the percent recovery of CTCs obtained using the high throughput microfluidic 
device described previously with different surface processing conditions to enhance the recoveries.2  The 
effects of anti-EpCAM antibody concentration on the percentage of breast cancer CTCs recovered will 
also be investigated. 
2.2 Materials and Methods 
      PMMA substrates and cover plates (0.5 mm thickness) were purchased from Good Fellow (Berwyn, 
PA).  Polyimide-coated fused silica capillaries were purchased from Polymicro Technologies (Phoenix, 
AZ).  Chemicals used for the PMMA surface cleaning and modification included reagent grade isopropyl 
alcohol, 1-ethyl-3-[3-dimethylaminopropyl] carbodimide hydrochloride (EDC), N-hydroxysuccinimide 
(NHS), fetal bovine serum and 2-(4-morpholino)-ethane sulfonic acid (MES) and these were purchased 
from Sigma-Aldrich (St. Louis, MO). Monoclonal anti-EpCAM antibody was obtained from R & D 
Systems (Minneapolis, MN).   The MDA-MB-231 cells were cultured at the Louisiana State University 
Agricultural Science laboratory.  Phosphate buffered saline (PBS) was purchased from American Type 
Culture Collection (ATCC, Manassas, VA).  All solutions were prepared in 18 MΩ water.  PKH67, a 
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fluorescein derivative, which contained a lipophilic membrane linker for cell staining, was purchased 
from Sigma-Aldrich.3,4 
2.2.1 Cell Suspensions 
  MDA-MB-231 cells were cultured to 80% confluence in Dulbecco‘s Modified Eagle‘s Medium 
supplemented with high glucose containing 1.5 g L-1 sodium bicarbonate (NaHCO3), 15 mM HEPES 
buffer, and 10% fetal bovine serum. A 0.25% trypsin solution was prepared in 150 mM PBS and used to 
harvest the MDA-MB-231 cells from the culturing plate. 
     MDA-MB-231 cells were stained with PKH67 for microscopic visualization experiments using 
fluorescence. A modified protocol for cell staining was employed in which the dye concentration was 
increased twofold. This increase resulted in more evenly distributed fluorescent labels over the cell‘s 
periphery. Cell counts for seeding experiments into PBS buffer were determined by counting three 
aliquots of cells in succession using a hemacytometer.  
2.2.2 Fabrication of HTMSU 
 
      The HTMSU was hot embossed into PMMA substrates via micro-replication from a metal mold 
master.9  Fabrication of the HTMSU used protocols that have been previously reported.2 9 The HTMSU 
consisted of a series of 51 high-aspect ratio curvilinear channels that collectively formed the cell selection 
bed.  Each channel was 150 µm (depth) x 30 µm (width) and shared common inlet/outlet ports.  
Curvilinear-shaped capture channels were used to improve the capture efficiency as described previously. 
Curvilinear channels do not possess the cell-free marginal zone that occurs in straight channels. The use 
of curvilinear channels stops the cell radial distribution from being affected by changes in cell 
translational velocity.9  Centrifugal forces acting on the cells and the cross stream velocity component due 
to the reversal of the direction of curvature, causes the cells to migrate to the outside of the curved 
channels.2 This resulted in an increase in the antibody/antigen encounter rate as the cells moved through 
the capture beds at high-linear velocities, which resulted in high recoveries of the CTCs.3 The channel 
width of the cell capture bed (30 µm) was similar to the average target cell diameter.  This channel width 
was chosen to increase the probability of cell-antigen interactions with the target cells.  The large channel 
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depth (150 µm) was selected to decrease the pressure drop in high-volume flow rate operation and also to 
increase the sample processing throughput.3   In Figure 2, the entry (a) was connected to a T intersection 
labeled (e). All of the channels were rectangular in shape with dimensions of 50 µm x 100 µm, width and 
depth, respectively.2, 9  The chips were washed in micro 90 critical cleaning solution and 2-propanol.  
They were ultrasonicated for 25 min.  The channels were observed under a microscope to ensure that they 
were not filled with debris.  They were then dried overnight in an oven at 70°C.  
2.2.3 Antibody Immobilization to the HTMSU 
     The properly cleaned HTMSU substrates and cover plates were exposed through a mask to UV 
radiation, which resulted in regio-specific carboxylation only in the exposed areas of the PMMA.9  
 
 
  
Figure 2.1 (A) Diagram of the HTMSU made via micro-replication into PMMA from a metal mold 
master. The capture bed consisted of curvilinear channels that were 30 µm wide and 150 µm deep (51 
channels). (B) Antibody immobilization scheme for the selection of MDA-MB-231 cells. Also shown is 
the chemistry used for the immobilization of the EpCAM antibodies to the PMMA surface. The first step 
involved the UV-irradiation (20.76 mW/ cm2) of PMMA and in this case, the irradiation was carried out 
on just the capture bed so that positive cell selection occurred only in this region.2 
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UV radiation was exposed through a mask for 5, 10, 15 or 20 min at 20 mW cm-2 to generate an activated 
surface that included a carboxylic acid scaffold.3,4   The EpCAM antibody immobilization scheme is 
shown in Figure 2.1.  The UV-modified HTMSU device was infused with a solution that contained 6 
mg/mL EDC, 40 mg/m NHS in 150 mM MES (pH = 6). The device containing the EDC/NHS reaction 
mixture was then incubated for 15 min at room temperature in order to produce a succinimidyl ester 
intermediate.  Following incubation, the EDC/NHS solution was removed by flushing nuclease-free water 
through the device.   
        Antibody immobilization to the HTMSU device’s microchannel walls was initialized by introducing 
a 0.25, 0.5, 1.0 or 2.0 µg/µL aliquot of monoclonal anti-EpCAM antibody solution contained in 150mM 
MES (pH = 6) into the microfluidic device. The antibody infused device was then allowed to react 
overnight in darkness and moisture.  To facilitate EpCAM antibody immobilization exclusively, the 
device was then rinsed with PBS solution (pH = 7.4) to remove any non-specifically bound EpCAM 
antibodies.9 
2.2.4 MDA-MB-231 Cell Capture Using the HTMSU 
     The HTMSU was connected to a PHD2000 syringe pump (Harvard Apparatus, Holliston, MA using a 
luer lock syringe (Hamilton, Reno, NV) that was modified with a luer-to-capillary adapter (Inovaquartz, 
Phoenix, AZ).9 This was then attached to the capillary that was sealed to the input port of the HTMSU. A 
pre-capture rinse was performed with 0.2 mL of 150 mM PBS at 50 mm s-1 linear velocity to maintain 
isotonic conditions. Then, 1mL of the cell suspension was introduced at a flow rate of 27.5 µL/min to 
produce the desired linear velocity in each microchannel that comprised the capture bed. Next, a post-
capture rinse was performed with 0.2 mL of 150 mM PBS (pH = 7.4) at 50 mm s-1 to remove any non-
specifically adsorbed cells. In order to optically visualize the captured cells, the PMMA devices were 
fixed onto a programmable motorized stage of an Axiovert 200M (Carl Zeiss, Thornwood, NY) 
microscope and video images were collected during each experiment at 30 frames per second using a 
monochrome CCD (JAI CV252, San Jose, CA). A Xe arc lamp was used to excite the fluorescent dyes 
incorporated into the cells membrane.4 Cells were quantified in one channel using a hemacytometer.  The 
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number of cells counted in one channel was multiplied by 51 to aid in the determination of percent 
recoveries. 
2.2.5 IR Measurements of UV-Modified PMMA 
       IR spectra of pristine and UV modified PMMA (5, 10, 15, 20 min) was obtained using a Bruker 
Tensor 27 FT-IR.  The standard sample cell was a Pike Miracle single-bounce attenuated total reflectance 
(ATR) cell equipped with a ZnSe single crystal.  ZeSe absorbs strongly below 650cm-1.  The IR beam 
penetrated approximately 60 µm into the surface of the PMMA.  Background spectra were collected 
before each measurement. 
2.3   Results and Discussion 
      The analysis of breast cancer CTCs is challenging and often results in low cell recoveries and poor 
reproducibility.7  The low recoveries are related to the rarity of CTCs in human blood (~10 cells/mL of 
whole blood). CTC isolation techniques, such as immunomagnetic bead purification, (i.e. CellSearch) 
isolate small numbers of CTCs (4 ±2) per ml in lung; 11 ±12 in breast; 10 ±33 in prostate; and 1 ±2 in 
both colorectal and pancreatic cancers with very low purity (0.01–0.1%), and low yield (20–60% of 
patients).10 	  	  	  	  	  Microsystem platforms allow one to manipulate small numbers of cells without loss of sample.7  
Eliminating cell loss is difficult when using macro-scale techniques, such as flow cytometry, which 
requires a starting population of more than 100,000 cells.6  One challenge in utilizing low-abundance cell	  
selection assays using microsystems is sampling; the ability to generate a high statistical probability of 
selecting the low-abundance cells requires large input volumes (>1 mL) to be processed, and most 
microsystems cannot handle large-volume inputs in reasonable times (i.e., they have poor throughput).7  
This creates the necessity for a novel microfluidic design that will accommodate the appropriate 
sample volume.7 The capture of breast cancer CTCs using the HTMSU has been previously reported by 
Adams et al.2 The MCF-7 cell line was used as a model for CTC selection and enumeration via and 
HTMS, which has an EpCAM expression level of 222.1 X 103  per cell.2   Using the MCF-7 cell line, 
recoveries of 97% were achieved using this microfluidic device.2   
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      The work reported herein will show that CTCs exhibiting low EpCAM expression levels can be 
recovered with high efficiency using similar methods as reported by Adams et al. and Dharmasiri et al, 
but with special surface designs/chemistry imparted to the capture bed.2 9 The device used by Andre et al. 
has the ability to improve the recovery low expression EpCAM cells because it possesses design rules and 
integration methods capable of changing the surface chemistry without sacrificing its current operational 
metrics.2  The system employs efficient high-aspect ratio capture beds. The 51 channels in this capture 
bed are covalently decorated with EpCAM antibodies through an EDC-NHS reaction. The low EpCAM 
expressing MDA-MB-231 cell line was utilized for selection of these CTCs to evaluate methods to 
improve the positive selection of these types of cells. Specifically, we will investigate UV modification 
time, which not only generates functional groups for antibody attachment, but also can generate 
nanotextured surfaces. The antibody concentration used for the attachment reaction will also be 
investigated. Finally, surface characterization techniques will be undertaken as well. 
2.3.1 Percent Recovery of CTCs as a Function of UV Modification Time 
       It has been determined that surface carboxylic acid groups are formed when PMMA surfaces are 
exposed to UV irradiation and the resulting surface carboxylic acids allow for further functionalization of 
PMMA-based microfluidic devices.11  
 
Figure 2.2  (A) Pristine PMMA reacted with Tl(OEt) yields no reaction. (B) UV-modified PMMA reacts 
with Tl(OEt) to yield Tl labeled PMMA. 
 
     In addition, the UV exposure induces photoablation that also creates nanotextured surfaces. This 
concept was further supported by Batich et al., who utilized element specific labeling of UV activated 
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PMMA surfaces.12  As outlined in Figure 2.2, Tl (oEt) specifically reacts with carboxylic acid groups, but 
not ester groups, and therefore the amount of Tl coupled to the polymer surfaces will reveal the number of 
accessible carboxylic acid groups formed on the polymer.12 
   UV modification was used to generate a carboxylate scaffold on the walls of the HTMSU channels and 
then, a EDC-NHS reaction was used to generate reactive intermediates that possess the ability to 
covalently attach to anti-EpCAM antibodies.2 The capture of MDA-MB-231 cells occurs through the 
affinity of anti-EpCAM antibodies immobilized to the PMMA surface for the EpCAM antigen that is 
expressed on the surface of breast cancer CTCs, namely MDA-MB-231 cells. Herein, the effects of varied 
UV modification times on the percentage of CTCs recovered by the HTMSU device was explored. 
     The capture bed of the PMMA substrate was exposed to UV irradiation (21.8 mW/cm2 ) for 5, 10, 15 
and 20 minutes. After thermal fusion bonding of the cover plate and substrate to enclose the fluidic 
network and the application of the EDC-NHS reaction to immobilize the anti-EpCAM antibodies to the 
HTMSU channel walls, fluorescently labeled MDA-MB-231 cells were infused into the device at a rate of 
27.5 µL/min.  Cells were visualized using a Zeiss Axiovert 200M microscope. Table 2.1 shows this data. 
Table 2.1 Percent recovery of MDA-MB-231 CTCs versus UV-modification time.  
UV Modification Time (min) Mean Recovery (%) n=3 
5 58 ±2 
10 82 ±2 
15 82 ±3 
20 78 ±6 
       
     UV modification times as low as 5 min were sufficient for the efficient capture of this low expression 
level breast cancer CTCs.  However, the highest recovery was generated for a 10 min UV modification 
time, where the recovery was found to be 82 ±2%. 
2.3.2 IR Spectra of Pristine and UV Modified PMMA  
    
     To obtain evidence of the generation of carboxylic acids as a result of UV modification, IR spectra 
were collected of pristine PMMA and PMMA that had been exposed to UV irradiation for 5, 10, 15 and 
20 minutes. Figure 2.3 shows the IR spectra for pristine PMMA and a 10 min UV modification time, 
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Figure 2.3 (A) IR spectrum of pristine PMMA. (B) IR spectrum of PMMA that was UV 
modified (20.8 MW/cm2) for 10 min.  
 
which was shown to be the optimal modification time in Section 2.3.1. These spectra were obtained in 
order to visually observe the chemical changes that occurred during UV modification. The FT-IR 
spectrum of pristine PMMA in Figure 2.3a displays the details of functional groups that are present in 
PMMA.  The sharp intense peak at 1726 cm-1 appeared due to the presence of an ester carbonyl group 
stretching vibration.13  The broader peak seen at 1449 cm-1 is due to the C-0 (ester bond) stretching 
vibration.13 The broad peak seen around 2959 cm-1 is due to an alkane (C-H) stretching vibration. 
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      As the PMMA was UV irradiated beginning with its pristine state to 20 min of exposure, the intensity 
of the ester group peaks decreased.  Although there were differences observed in the intensities of the 
ester group peaks, these differences were minimal and unfortunately, did not conclusively provide 
evidence of the generation of carboxylic acids groups on the PMMA surface due to UV modification.  
The IR beam of the Bruker Tensor FT-IR penetrates ~60 µm into the bulk PMMA.  However, UV 
modification has been shown to penetrate only 6 - 8 µm into the PMMA.14 Due to the high penetration 
depth of the IR beam, the ATR-IR spectra are dominated by the bulk material and not surface material 
and as such, the surface changes are masked. A better approach may be to use the chemistry delineated in 
Figure 2.2. 
2.3.3 Percent Recovery as a Function of EpCAM concentration 
     Further investigation of the ability of anti-EpCAM antibodies to select low expressing breast cancer 
CTCs was explored by varying the concentration of the anti-EpCAM antibody used for the reaction. 
Successful capture of the CTCs using small concentrations of anti-EpCAM antibodies  (i.e. 0.25 µg/µL) 
could afford the ability to use less anti-EpCAM antibody material and reduce the cost of producing the 
device as well.  
     Using the same protocol and optimal UV modification time of 10 min, EpCAM antibody 
concentrations of 0.25, 0.5, 1.0 and 2.0 µg/µL EpCAM were allowed to react with the succinimidyl ester 
formed by the EDC-NHS reaction.  
Table 2.2 Percent recovery of CTCs as a function of antiEpCAM antibody concentration 
antiEpCAM Antibody  
Concentration (µg/µL ) 
Mean Recovery (%) n=3 
0.25 71 ±2 
0.5 82 ±1 
1.0 82 ±2 
2.0 80 ±3 
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      In Table 2.2, it was observed that when using an anti-EpCAM antibody concentration of 0.25 µg/µL, a 
recovery of 71 ±2% was obtained. A maximum percent recovery of 82 ±1 % was observed at 
concentrations of 0.5 and 1 µg/µL of the antibody. 
     The percent recoveries obtained, indicated that an anti-EpCAM concentration of 0.25 µg/µL does not 
provide as many immobilized antibodies for cell capture as 0.5 and 1.0 µg/µL concentrations. The 
recovery of 82% at concentrations of 0.5 and 1.0 µg/µL could indicate that the channels become saturated 
with immobilized antibodies at this point and therefore, the recovery does not vary.  When an even higher 
anti-EpCAM antibody concentration of 2 µg/µL was used, the recovery slightly decreased to 80 ±3%. 
2.3.4 Plasma Oxidation vs. UV Modification 
      Plasma oxidation is another method for decorating the walls of the microfluidic channels with 
carboxylic acid groups to allow for anti-EpCAM antibody attachment. Surface modification of the 
PMMA occurs when the plasma impinges on the PMMA surface with high energy gas molecules that can 
result in a variety of reactions on the surface of the PMMA.14 Herein, we explored the effects of using 
plasma oxidation as the surface modification method for antibody immobilization instead of UV 
modification.  The goal was to determine if a plasma oxidized HTMSU would yield higher recoveries to 
those obtained using a UV modified HTMSU.  Plasma oxidation was done for 2 min.  The CTC percent 
recoveries are shown in Table 2.3.  Brown et al. conducted experiments to determine the extent of 
reaction and the amount of carboxylic acid groups formed on the surface of plasma treated PMMA.14  The 
polymer was modified with N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide (WSC), which binds 
selectively and quantitatively to carboxylic acid groups. The change in WSC concentration was measured 
after the removal of PMMA.  It was found that after 10 s of plasma exposure, there was an increase in 
carboxylic acid groups (210 ±70 nmol cm-2).14  UV modification of PMMA follows a similar pattern.15  
Wei et al demonstrated that  the surface concentration of carboxylate groups on PMMA surfaces 
increases consistently  with increases in photochemical modification time up to 30 min.  The surface 
coverage of carboxylic acid sites on PMMA surfaces can go as high as 1.68 nmol cm-2.15   
     However, in the case of plasma oxidized surfaces, at longer exposure times, a decrease in carboxylic 
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acid concentration on the surface was observed.14 The results shown in Table 2.3 were obtained after 2 
min of plasma oxidation treatment. 
Table 2.3 CTC Percent recovery obtained via plasma oxidation for 2 min. 
 
 
 
 
 
      
 
 The percent recoveries obtained were lower than those obtained using UV modification.  The lower 
recoveries observed could have been due to a lower number of carboxylate groups that were available for 
antibody attachment for the plasma treated surface.  It has also been reported that plasma oxidized 
PMMA shows an increased hardness on the surface.  This hardness is due to the formation of a brittle 
layer that arises from the formation of not only carboxylate groups, but also oxides and anhydrides in the 
exposed region.14 The combination of functional groups that are formed as a result of plasma oxidation 
(carboxylates and oxides) could also be a contributing factor to the lower recoveries obtained in 
comparison to those of a UV modified HTMSU, which may produce lower levels of non-carboxylic acid 
groups.  
       Because increased roughness values have been associated with higher recoveries of CTCs, AFM 
images of plasma oxidized and UV modified PMMA were obtained.16  These AFM images were used to 
quantify the differences in roughness between plasma oxidized and UV modified PMMA.  Figure 2.4 
displays these images.  AFM measurements were obtained for pristine, 30 s plasma oxidized and 10 min 
UV modified PMMA.  The roughness values of these modified PMMA surfaces were determined to be 
2.2 ± 0.6 nm, 5.5 ± 0.8 nm and 6.6 ± 0.5 nm, respectively.  The UV modified surface had the highest 
roughness and did yield the highest recovery of CTCs (82%).  
 
Cells Infused Into 
System 
Cells 
Captured 
Percent Recovery 
500 240 48% 
500 255 51% 
500 255 51% 
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Figure 2.4 AFM images of modified PMMA (A) AFM image of pristine PMMA. (B) AFM image of 30s 
plasma oxidized PMMA (C) AFM image of 10 min UV modified PMMA. 
 
2.4 Conclusions 
      Breast cancer CTCs that have low expression levels of EpCAM (MDA-MB-231) can be successfully 
selected using the HTMSU shown in Figure 2.1, containing channels that have been covalently decorated 
with anti-EpCAM antibodies. When varying UV modification times of the PMMA (5, 10, 15 and 20 
min), a maximum CTC recovery of 82% was achieved when the exposure time exceeded 10 min.  The 
effects of using different concentrations (0.25, 0.5, 1 and 2 µg/µL) of anti-EpCAM antibody were 
investigated as well.  It was found that using anti-EpCAM antibody concentrations as low as 0.25 µg/µL, 
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71.4% of the cells were recovered.  A maximum recovery of 82% was obtained using anti-EpCAM 
antibody concentrations of 0.5 and 1.0 µg/µL. 
      When comparing CTC recovery using UV modified microfluidic devices to those that were treated 
using plasma oxidation, it was determined that the percentage of cells recovered from the latter 
modification method were lower (51%) compared to the UV modified surfaces.  This is most likely due to 
the fact that plasma oxidation generates hydroxyl and carboxylate groups on the surface of PMMA and 
the modification chemistry employed was specific for carboxylic acid groups only.14 In contrast, UV 
modification exclusively generates carboxylate groups on the surface, therefore allowing for the 
formation of a greater number of reactive intermediates that will tether to the anti-EpCAM antibodies for 
CTC selection. 
Using UV activation of the appropriate time, sufficient amounts of antibody, we have demonstrated 
that CTCs typically viewed as EpCAM-negative can be selected from clinical samples. This is attractive, 
because in most cases, the CTCs selected from a patient represent a heterogeneous population with a large 
spread in the EpCAM expression level. Therefore, precise CTC numbers can be collected for these 
patients to better predict patient outcomes from the selected therapy or even guiding therapy. In addition, 
the higher recovery for even low-expression level CTCs will provide a greater yield to aid in the 
subsequent molecular profiling of the CTCs from a single patient to help manage his/her particular 
disease.  
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CHAPTER 3. FUTURE WORK: MOLECULAR PROFILING OF CTCs  
 
3.1 Introduction 
 
       Analysis of CTCs, for example in the case of breast cancer, is important because of its utility in 
patient prognosis and potentially diagnosis as well as monitoring for disease recurrence or determining the 
effectiveness of treatment. CTCs in the blood have been shown to be an important indicator of the 
potential for relapse and ultimately metastatic disease.1 Once the CTCs are selected, a means of 
determining their gene expression is necessary to decipher the activity of genes involved in the patient’s 
cancer disease. Determining the gene expression profiles of CTCs is important because changes in the 
phenotype of the CTCs can occur after the original diagnosis.2   Figure 3.1 outlines the genetic flow of 
information, which is necessary when defining gene expression. A gene is a region of DNA that controls 
hereditary characteristics.3 Genes are expressed as the proteins they encode. It occurs in two steps, 
transcription, followed by translation. Therefore, disregulation occurring due to uncontrolled cell growth, a 
common phenomena in cancer, can produce proteins that are disregulated as well.  
         Resistance to treatment is only determined after the treatment has failed.2  Molecular profiling, of 
which gene expression profiling is one type of molecular assay, is one way to make this determination.2 It 
can be described as the classification of tissue or other specimens for diagnostic and predictive purposes 
based on multiple gene expression.4  This information has the potential to improve the management of a 
cancer patient’s treatment regime.3   Knowledge of genetic alterations or gene expression perturbations in 
cancer patients can decrease toxicity by avoiding unnecessary therapy in patients who have an excellent 
prognosis without requiring the need for chemotherapeutic treatment and in those who are deemed 
unresponsive to a particular therapy.5  Breast cancer was the first cancer-related disease that molecular 
profiling has been approved for clinical use.2 Molecular profiling differs from standard methodologies 
because it allows tumors to be defined by the expression pattern or genomic alteration of thousands of 
genes simultaneously instead of relying on a few pathological features and immunohistochemical 
markers.6   
      There are a number of different molecular profiling techniques including gene expression profiling.  A 
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Figure 3.1 (A) The flow of genetic information is unidirectional, from DNA to protein with messenger 
RNA as an intermediate (B) Genetic Flow of Information: Proposed by Francis Crick in 1958 to describe 
the flow of information in a cell. 3 
major difficulty encountered when choosing a molecular profiling technique is that many cancers, such as 
breast cancer, are highly heterogeneous and contain a mixture of benign, cancerous and stromal cells 
when performing the analysis directly on tumor tissue.7 Current methodologies such as RT-PCR, gene 
chips, protein chips, 2D gel electrophoresis and biomolecular mass spectrometry are not designed to 
handle heterogeneous samples with sufficient reliability.7 In contrast, high-throughput techniques, such as 
microarray analysis, provide knowledge of mutations or epigenomic changes in certain genes and 
prognostic and predictive models on the basis of mRNA and microRNA (miRNA) expression profiles.8  
This high throughput technique is an excellent methodology that can prevent excessive or insufficient 
treatment of cancer patients, however most of these prognostic models are based on the primary tumor 
and not the subsequent metastasis that occurs.8 Metastasis, which can develop years after the occurrence 
of the primary tumor, can possess great genetic differences from the tissue of the primary tumor.8  It is 
therefore anticipated that molecular profiling of metastasis will improve current prognostic models.8  This 
can be achieved through molecular characterization of CTCs.8 The molecular profiling technique that will 
be the focus of this chapter will be gene expression profiling.  One application for gene expression 
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profiling is the use of microarrays.9  This technology brings the prospect of defining individual genes or 
combinations of genes whose expression levels can differentiate between clinically significant subtypes of 
breast tumors that require different treatment strategies.5 
3.2 Molecular Classification of Breast Cancer 
There are various gene mutations that can be expressed by a particular breast cancer disease of a 
patient.  The identification of these mutations give physicians a better insight into the types of therapy 
that will be needed and the patient’s likelihood for relapse.10  Biological evidence for the heterogeneity of 
breast cancer has also been provided through molecular profiling. Heterogeneity essentially means that 
the response to treatment and the prognosis of two patients with the same stage of breast cancer can be 
considerably different. 2 The intrinsic subtypes of breast cancer, such as Luminal A, Luminal B, 
HER2+/ER- have been distinguished by gene expression profiling.11  Perou et al. first identified distinct 
subtypes of breast cancer using unsupervised hierarchal analysis of gene expression pattern differences 
identified in 65 breast cancer specimens.12  The sub-classification of breast cancer tumors into luminal 
and basal-like types originated from comparing gene expression patterns with those of epithelial cells that 
are normally found in non-malignant human mammary gland tissues.11  Perou et al. proposed that these 
four classes could be called basal-like cancers, which mainly corresponded to ER-negative, progesterone-
receptor (PR) negative and HER2 negative tumors, luminal-A cancers, which are mostly ER positive, 
luminal B cancers, which are like luminal-A, but may also express low levels of hormone receptors, and 
HER-2 positive cancers that show amplification and high expression of ERBB2. Luminal types of tumors 
have been shown to express high levels of luminal cytokeratins and genetic markers of luminal epithelial 
cells of normal breast tissue through microarray studies.11 
      In contrast, basal-like breast cancers do not express ER, PR, and ER-related genes and do not 
overexpress several genes that typify myoepithelial cells of normal breast tissue, luminal cytokeratins, 
smooth-muscle–specific markers, and certain integrins.7 In some basal-like cancers, there is high 
expression of “basal” cytokeratins, such as CK5 and a variety of growth factor receptors, including high 
levels of epidermal growth factor receptor, c-kit (a tyrosine kinase in breast epithelium), and growth 
	   37	  
factors such as hepatocyte growth factor and insulin growth.7 
3.3 Current Methods of Breast Cancer Gene Expression Profiling: Microarrays 
Gene expression microarray analysis has a potential role for predicting relapse.6 Currently, the 
majority of scientific analyses conducted focus on the manipulation and interpretation of cDNA arrays 
that are generated by converting mRNAs that have been isolated from various tissue types into cDNAs.  
These cDNAs are fixed to a solid substrate and then quantified.9   The principle of a microarray 
experiment is that mRNA from a given cell line or tissue is used to create a labeled sample, the target, 
which is hybridized in parallel to a large number of DNA sequences immobilized on a solid surface in an 
ordered array.9   Researchers are then able to compare the expression of cDNAs isolated from different 
tissue types.  From the comparative data gathered, scientists are able to better elucidate the biology of 
each tissue type.5 This technology has the ability to detect and quantify tens of thousands of transcript 
species simultaneously.9  
     There are two main types of microarray systems; complementary DNA (cDNA) and oligonucleotide 
microarrays (Figure 3.2).9 Included in the cDNA system is a probe, which is the arrayed material.  The 
probes that are generated are PCR products from cDNA libraries or gene specific primers 
(oligonucleotide).  They are printed onto glass slides or nylon membranes as spots at defined locations.  
These spots can range from 100-300 µm in size and are spaced equal distance apart. Arrays of more than 
30,000 cDNAs can fit onto arrays the size of a conventional microscope slide.  In the case of 
oligonucleotide arrays, short 20-25mers are synthesized in situ and printed onto glass slides.  The 
oligonucleotide method is advantageous because the sequence information alone can be used to generate 
the DNA to be arrayed.9 Some disadvantages are encountered because the oligonucleotide method is 
expensive and the use of short oligonucleotides result in less specific hybridization and reduced 
sensitivity.9  Microarray experimental data consists of a long list of measurements of spot intensities and 
intensity ratios.  These measurements are generated by comparing two samples pairwise or by comparing 
several samples to a common control. 
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Figure 3.2 Schematic overview of probe array and target preparation for spotted cDNA microarrays and 
high-density oligonucleotide microarrays. a, cDNA microarrays. b, High-density oligonucleotide 
microarrays9 
 
Following this, the challenge is to sieve through large amounts of data to find results that are significant 
and meaningful. It has also been discovered that significant variability issues can occur and replication is 
required to develop a high degree of confidence in the data.  Often, subsets of results have to be verified 
through alternative techniques such as northern hybridization, RNase protection or PCR with RT-PCR.  
     Overall, microarray technology is capable of differentiating between different subtypes of breast 
cancer.9 The biochemistry of microarrays has been proven to be highly useful in developing a complete 
understanding of the molecular differences in breast cancer samples.3 
3.4 Future Work Proposal 
      Evidence presented in Chapter 2 has already shown that breast cancer CTCs that have low expression 
levels of EpCAM can be successfully captured using a microfluidic device that has been covalently 
decorated with anti-EpCAM antibodies. This is particularly important for breast cancer, because there are 
different breast cancer sub-types of various levels of EpCAM expression. For example, claudin-low cells 
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such as MDA-MB-231, have low EpCAM expression levels and as such, typical positive selection 
systems due to possess the capability to select these cells. With the discoveries emanating from this 
 
 Figure 3.3 Diagrams showing the microfluidic system, which included the HTMSU and the 
electromanipulation unit. (A) The capture bed consisted of a series of 51 curvilinear channels (30 µm 
wide and 150 µm deep). The electromanipulation unit contained 80 µm wide, 100 µm deep, and 5 cm 
long linear channels. Conductometrically enumerated CTCs were introduced into the electromanipulation 
unit at port a, which served as the entrance port. Port a was connected to a “T” junction labeled e. Exit b 
served as the sample waste reservoir, while reservoir c was the CTC receiving reservoir (anodic 
reservoir). (B) Brightfield (left) and fluorescence (right) micrographs (40_) of selected SW620 CTCs 
using the HTMSU. (C) The selected SW620 CTCs were enriched into reservoir c due to their intrinsic 
electrophoretic mobility and the applied electric field. The total volume of the receiving reservoir was 2 
µL.13 
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work, the use of UV activation and sufficient amount of anti-EpCAM antibodies can generate surfaces 
that can recover these type of cells with excellent recovery. 
The analysis of captured breast cancer CTCs can be taken a step further through molecular profiling.  
Dharmasiri et al. used a similar concept for the capture, enumeration, electrokinetic manipulation and 
molecular profiling of colorectal CTCs.13 This study employed a microfluidic electrokinetic manipulation 
unit interfaced to a fluidic chip to select SW620 and HT29 cells (Figure 3.3). 
      The microfluidic device was previously described by Adams et al. 14  The electro-manipulation unit 
contained one entry, through reservoir a and two exits, via reservoirs b and c.  Reservoir a was connected 
to a “T” intersection that is labeled e in Figure 3.3. All of the channels were rectangular and had 
dimensions of 80 µm x 100 µm, width and depth, respectively.  Pt wires of 125 µm were used as external 
electrodes in the b and c reservoirs of the electromanipulation unit.14  SW620 and HT29 CTCs were 
captured specifically based on the recognition abilities of anti-EpCAM antibodies that were covalently 
immobilized to the walls of the HTMSU selection bed.12  The curvilinear channels of the HTMSU 
ensured that a high number of cell/wall interactions occurred to improve the recovery.15 Observation of 
the selected cells was done using fluorescence and brightfield microscopy.  The captured cells were 
released using 0.25% trypsin, which enzymatically digested the extracellular domain of EpCAM and/or 
anti-EpCAM antibodies.13 The average release time was ~16 min. The selected and released cells were 
then enumerated using conductivity detection.13 Once released, the CTCs were collected and subjected to 
a mutation detection assay to look for point mutations in the genomic DNA of the selected CTCs; in this 
case, Kras mutations were analyzed.  This unit used hydrodynamic flow and an electric field to direct 
CTCs released from the selection surface into a reservoir to allow molecular analysis of low numbers of 
CTCs.15  In this study, KRAS mutations in the CRC cell lines SW620 and HT29 were used as a model. 
KRAS mutations are indicative of very poor response to panitumumab and cetuximab therapies in 
colorectal cancers. 15 A PCR coupled to a ligase detection reaction (LDR) assay was conducted on codon 
12 of the KRAS oncogene of the CTCs. Successful PCRs on 10 CTCs selected from the HTMSU were 
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confirmed by positive and negative control experiments.  The resulting PCR/LDR products were analyzed 
using capillary gel electrophoresis (Figure 3.4). 13 
 
 
Figure 3.4 Overview for the Cell Selection, Enumeration, Electrokinetic Enrichment, and Molecular 
Profiling Strategy Adopted for the Analysis of Low-Abundance CTCs Resident in Peripheral Blood13 
  
       This work explored the idea that immunoaffinity-based selection of CTCS combined with genotyping 
of the selected CTCs for the presence and absence of certain mutations can give valuable information that 
will help physicians to determine which treatment regime should be used for a particular colorectal cancer 
patient.13 Dharmasiri et al. were able to demonstrate the ability to recover CTCs with 96 ± 4% efficiency 
from whole blood and ~100% electrokinetic enrichment of the selected CTCs.13   Ten CTCs isolated from 
whole blood were successfully genotyped.13 
      Given the success of Dharmasiri et al., herein a method is proposed to obtain molecular profiles, of 
breast cancer CTCs that have been selected using a HTSMU. The abnormal activation of HER1 and 
HER2 has been linked to various types of breast cancer progression.  It has also been reported that there 
are frequent and significant changes in their expression status between primary tumor and CTCs. 10 
Obtaining a molecular profile of these genes from captured breast cancer CTCS using microarray analysis  
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may provide better insight into the diseases profile shift and ultimately lead to better selection of therapy 
for individual patients. 10 
3.5 Materials and Methods 
 
     PMMA substrates and cover plates (0.5 mm thickness) will be purchased from Good Fellow (Berwyn, 
PA).  Polyimide-coated fused silica capillaries will be purchased from Polymicro Technologies (Phoenix, 
AZ).  Chemicals used for the PMMA surface cleaning and modification will include reagent grade 
isopropyl alcohol, 1-ethyl-3-[3-dimethylaminopropyl] carbodimide hydrochloride (EDC), N-
hydroxysuccinimide (NHS), fetal bovine serum and 2-(4-morpholino)-ethane sulfonic acid (MES) and 
these will be purchased from Sigma-Aldrich (St. Louis, MO). Monoclonal anti-EpCAM antibody will be 
obtained from R & D Systems (Minneapolis, MN).   The MDA-MB-231 cells will be cultured at the 
Louisiana State University Agricultural Science laboratory.  Phosphate buffered saline (PBS) will be 
purchased from American Type Culture Collection (ATCC, Manassas, VA).  All solutions will be 
prepared in 18 MΩ water.  PKH67, a fluorescein derivative, which contains a lipophilic membrane linker 
for cell staining, will be purchased from Sigma-Aldrich.3,4 
3.5.1 MDA-MB-231 Cell Suspensions 
     MDA-MB-31 cells will be cultured to 80% confluence in Dulbecco‘s Modified Eagle‘s Medium 
supplemented with high glucose containing 1.5 g L-1 sodium bicarbonate (NaHCO3), 15 mM HEPES 
buffer, and 10% fetal bovine serum.15 A 0.25% trypsin solution will be prepared in 150 mM PBS and 
used to harvest the MDA-MB-31 cells from the culturing plate.  
     MDA-MB-231 cells will be stained with PKH67 for microscopic visualization experiments using 
fluorescence. A modified protocol for cell staining will be utilized whereby the dye concentration will be 
increased two-fold resulting in more evenly distributed fluorescent labels over the cell‘s periphery. Cell 
counts for seeding experiments into whole blood will be determined by counting three aliquots of cells in 
succession using a hemocytometer.15  
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3.5.2 Fabrication of HTMSU 
The microfluidic device will be fabricated using the same methods previously reported by Adams et. al.14  
Briefly, The HTMSU (Figure 3.3 A) will be hot embossed into PMMA substrates via micro-replication 
from a metal mold master.  Fabrication of the HTMSU will follow steps previously reported.14, 16 The 
HTMSU will consist of a series of 51 high-aspect ratio curvilinear channels that in concert formed the cell 
selection bed.  Each channel will have 150 um (depth) x 30 um (width) and shared common inlet/outlet 
ports.14 
3.5.3 Antibody Immobilization to HTMSU 
         A UV-modified HTMSU device will be infused with a solution that contains 6 mg/mL EDC, 40 
mg/m NHS in 150 mM MES (pH=6) and will be incubated for 15 min at room temperature in order to 
generate a succinimidyl ester intermediate.  Following incubation, the EDC/NHS solution will be 
removed by flushing nuclease-free water through the device.  Then, a 0.5 µg/µL aliquot of monoclonal 
anti-EpCAM antibody solution will be dissolved in 50 mM PBS (pH = 7.4) and will be injected into the 
HTMSU and allowed to react overnight.  The device will then be rinsed with a PBS solution (pH = 7.4) to 
remove any non-specifically bound anti-EpCAM antibodies.15 
3.5.4 MDA-MB-231 Cell Capture Using the HTMSU and Release 
      The HTMSU will be connected to a pump using a luer lock syringe (Hamilton, Reno, NV) equipped 
with a luer-to-capillary adapter (Inovaquartz, Phoenix, AZ). This will then be attached to a capillary that 
is sealed to the input port of the HTMSU. A pre-capture rinse will be performed with 0.2 mL of 150 mM 
PBS at 50 mm s-1 linear velocity to maintain isotonic conditions.15 Then, the appropriate volume of a cell 
suspension will be introduced at the necessary volumetric flow rate to produce the desired linear velocity 
in each microchannel comprising the selection bed. Next, a post-capture rinse will be performed with 0.2 
mL of 150 mM PBS (pH = 7.4) at 50 mm s-1 to remove any non-specifically adsorbed cells. In order to 
optically visualize the selected cells, the PMMA devices will be fixed onto a programmable motorized 
stage of an Axiovert 200M (Carl Zeiss, Thornwood, NY) microscope and video images will be collected 
during each experiment at 30 frames per second using a monochrome CCD (JAI CV252, San Jose, CA).15 
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A Xe arc lamp will be used to excite the fluorescent dyes incorporated into the cells‘ membrane.  
Following a post-capture rinse, a 0.25% trypsin solution in 0.2 mM Tris/19.2 mM glycine buffer (pH = 
8.3) will be infused at 27.5 µL min-1 volumetric flow rate into the HTMSU.15 
3.5.5 RNA Isolation 
        For gene expression studies following the selection of CTCs using the HTMSU, CTCs will be lysed 
by adding 100 µL of Trizol reagent (Invitrogen, Carlsbad, CA).17  For all CTC samples, a CTC depleted 
blood fraction will be saved by withdrawing 100 µL of blood that will be recovered after CTCs are 
selected. This fraction will then be placed into a tube that will contain 900 µL of Trizol reagent.  RNA 
from all samples will be isolated using Trizol reagent based on the manufacturer’s instructions, DNase I 
treated and Trizol repurified.17 
3.5.6 Target Preparation, Microarray Hybridization and Microarray Data Analysis 
     10 ng of total RNA from the CTC enriched and CTC depleted fractions will be used to prepare 
biotinylated hybridization targets with Affymetrix’s eukaryotic small sample target labeling assay.17 This 
protocol is designed to reproducibly amplify 10 to 100 ng of total RNA and is based on the principal of 
performing two cycles of double-stranded cDNA synthesis and in vitro transcription reactions using T7 
RNA polymerase.17 Biotinylated target crane will then be hybridized to an Affymetrix Focus array based 
on manufacturer’s instructions.  Gene expression data will be obtained using Affymetrix Microarray 
Analysis Suite.17 
3.6 Expected Results and Significance 
     The anti-EpCAM antibodies will be covalently bonded to the channel walls.  This dynamic interaction 
between anti-EpCAM antibodies and the microchannel walls is necessary for the recovery of the breast 
cancer CTCs.15 When the breast cancer CTCs are infused into the system, they will be selectively 
immobilized.  The selected CTCs will be observed and enumerated using brightfield microscopy.  The 
cells will then be released from the capture bed via methods that will have minimal impact on the 
integrity and viability of the cell.15 
       Following their release, the RNA will be extracted from the CTCs for gene expression analysis 
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through the use of microarrays. This proposed method will offer the ability to obtain expression profiles 
for HER1 and HER2 expressed in breast cancer CTCs.  It is expected that by using a microarray based 
test, that multiple, distinct predictions, that include prognosis, ER and HER2 status and sensitivity to 
various treatment approaches will be generated from a single assay.10 Ultimately, this method should lead 
to the successful genotyping of CTCs, that have low EpCAM expression levels from whole blood.  
3.7 Clinical Implications 
    Being that EpCAM overexpression has been linked to poor prognosis and tumor invasiveness, a 
method that quickly selects and quantifies viable CTCs would prove to be beneficial in a clinical setting. 
CTC analysis could be used for diagnosis, prognosis and the prediction of treatment methods. The 
obtainment of CTCs is minimally invasive and would be done simply by drawing the blood of a patient in 
the clinic. The blood would then be infused into the same HTSMU used in Chapter 2 that consists of a 
capture bed that has immobilized EpCAM antibodies for the selection of cancer cells that express 
EpCAM14  Captured cells would then be released using trypsin.14   In a clinical setting, it would be 
unnecessary to visualize the CTCs using a microscope.  Clinicians would simply use the conductivity 
detector that is integrated into the microfluidic device.14 
 Cells would be hydrodynamcally driven through the conductivity sensor using a syringe pump at a 
controlled flow rate.  CTCs will then be detected based on their electrical properties that are unique in 
comparison to other cells found in whole blood samples.  These properties of CTCs make them good 
candidates for conductivity detection.  Based on the simple and low-cost production of these devices 
using microreplication technologies as well as their automated operation with no sample preprocessing 
required, the HTMSU would be a perfect fit in a clinic as a diagnostic tool for monitoring CTC levels in a 
variety of adenoma-based cancers for disease detection, cancer staging or evaluating the effectiveness of 
therapeutic intervention.14 
3.8 Thesis Summary 
      The thesis began with an overview of circulating tumor cells.  The term was defined and current 
methods for their analysis was discussed.  Chapter 2 focused on my project, which has been to determine 
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if breast cancer CTCs with low EpCAM expression levels could be captured using the same 
methodologies employed by Adams et al. and Dharmasiri et al.13, 16  The work described in Chapter 2 
confirmed that CTCs with low EpCAM expression levels can indeed be selected and enumerated with 
high efficiency.  It was also determined that the anti-EpCAM antibody concentration can be decreased to 
select these cells without significantly degrading the CTC recovery.  
      The thesis was concluded with Chapter 3, which initially described the advantages of taking the 
analysis of selected CTCs a step further through molecular profiling.  Current methods of molecular 
profiling were included.  Finally, future experimental methods for the molecular profiling of selected 
MDA-MB-31 cells via microarray based analysis were proposed. The overall clinical implications of the 
HTMSU for capture of CTCs was also discussed. 
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